|
|
|
|
| LEADER |
03498nam a22005055i 4500 |
| 001 |
978-1-4614-7654-2 |
| 003 |
DE-He213 |
| 005 |
20151218071850.0 |
| 007 |
cr nn 008mamaa |
| 008 |
130804s2013 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781461476542
|9 978-1-4614-7654-2
|
| 024 |
7 |
|
|a 10.1007/978-1-4614-7654-2
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Resistance to Immunotherapeutic Antibodies in Cancer
|h [electronic resource] :
|b Strategies to Overcome Resistance /
|c edited by Benjamin Bonavida.
|
| 264 |
|
1 |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2013.
|
| 300 |
|
|
|a XIII, 202 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 2
|
| 505 |
0 |
|
|a Preface -- Introduction and generation of chimeric and humanized mAbs -- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment -- Antibodies directed against different major cancers: Effects when used alone or in combination with drugs -- Mechanisms of antibodies-mediated responses, in vitro and in vivo -- Molecular Pathways -- Molecular Signatures -- Identification of resistance targets for intervention -- Various chemicals that can sensitize resistant tumor cells -- Other mAbs -- Proteasome inhibitors -- Divalent mAbs -- Antibodies coupled to chemical inhibitors -- Antibodies coupled to cytokines -- Nanoparticles with mAbs -- Index.
|
| 520 |
|
|
|a The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Antibodies.
|
| 650 |
|
0 |
|a Molecular biology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Molecular Medicine.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Antibodies.
|
| 700 |
1 |
|
|a Bonavida, Benjamin.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9781461476535
|
| 830 |
|
0 |
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 2
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-1-4614-7654-2
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
